Upgrade to SI Premium - Free Trial

Immunogen (IMGN) Reports Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab

March 26, 2018 6:12 AM
ImmunoGen, Inc. (NASDAQ: IMGN) today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles